Concepedia

Turja Chakrabarti

TC

Statistics

Publications

5

Citations

361

H-Index

5

Active since

2021

Affiliations

University of California, San Francisco(Current)

Dana-Farber Cancer Institute

University of California, Davis

University of Colorado Anschutz Medical Campus

Chan Zuckerberg Initiative (United States)

Turja Chakrabarti is an author at University of California, San Francisco specializing in medicine, oncology, and non-small cell lung cancer therapy.

Publications per year

2021–2024

5

Publications

5

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti et al. · Cancer Discovery · 2023 · 181 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

Collin M. Blakely, Anatoly Urisman, Matthew A. Gubens et al. · Journal of Clinical Oncology · 2024 · 57 citations · Full text

Medicine, Oncology, Pharmacology +16

Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy

Cole Friedes, Turja Chakrabarti, Sarah Olson et al. · Lung Cancer · 2021 · 54 citations

Medicine, Oncology, Radiation Oncology +17

Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

Sebastijan Hobor, Maise Al Bakir, Crispin T. Hiley et al. · Nature Communications · 2024 · 46 citations · Full text

Medicine, Molecular Genetics, Oncology +16

Phase II trial of neoadjuvant osimertinib for surgically resectable <i>EGFR</i>-mutated non-small cell lung cancer.

Jacqueline V. Aredo, Anatoly Urisman, Matthew A. Gubens et al. · Journal of Clinical Oncology · 2023 · 23 citations

Medicine, Oncology, Pharmacology +15

1–5 of 5